|
Anchala R, Kaptoge S, Pant H, Di Angelantonio E, Franco OH, Prabhakaran D. Evaluation of effectiveness and cost‐effectiveness of a clinical decision support system in managing hypertension in resource constrained primary health care settings: results from a cluster randomized trial. J Am Heart Assoc. 2015 5;4(1):e001213 Barnes VA, Pendergrast RA, Harshfield GA, Treiber FA. Impact of breathing awareness meditation on ambulatory blood pressure and sodium handling in prehypertensive African American adolescents. Ethn Dis. 2008;18(1):1-5. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal Eur Heart J. 2016 ;37(29):2315-81.. Carlos RC, Axelrod DA, Ellis, JH, Abrahamse RH, Fendrick AM. Incorporating patient-centered outcomes in the analysis of cost-effectiveness: imaging strategies for renovascular hypertension. AJR 2003; 181: 1653-1661. Chen T, Yu D, Cornelius V, Qin R, Cai Y, Jiang Z, Zhao Z. Potential health impact and cost-effectiveness of drug therapy for prehypertension. Int J Cardiol. 2017 Aug 1;240:403-408 Cheng, Hao-Min, et al. "Cost-effectiveness of noninvasive central blood pressure monitoring in the diagnosis of hypertension." American journal of hypertension 2014; 28.5: 604-614. Chiang CE, Wang TD, Ueng KC, et al. 2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. J Chin Med Assoc. 2015;78(1):1-47. Chiu, Yueh-Hsia, et al. Progression of pre-hypertension, stage 1 and 2 hypertension (JNC 7): a population-based study in Keelung, Taiwan (Keelung Community-based Integrated Screening No. 9). Journal of hypertension 2006; 24.5: 821-828. Chobanian, Aram V., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289.19: 2560-2571. Chuen-Den Tseng, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, Li-Sheng Chen,Hsiu-Hsi Chen and Shu-Hui Chang. A Predictive Model for Risk of Prehypertension and Hypertension and Expected Benefit After Population-Based Life-Style Modification (KCIS No. 24). American Journal of Hypertension 2012; 25(2): 171-9 Colhoun, Helen M., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. The Lancet 2004; 364.9435: 685-696. Collier, Scott R., and Michael J. Landram. Treatment of prehypertension: lifestyle and/or medication. Vascular health and risk management 2012; 8: 613. Cooney MT, Dudina A, Whincup P, Capewell S, Menotti A, Jousilahti P, Njølstad I, Oganov R, Thomsen T, Tverdal A, Wedel H, Wilhelmsen L, Graham I; SCORE Investigators. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil. 2009;16(5):541-9. Deng, Bing-Hwa, et al. "Cost-effectiveness of elderly health examination program: the example of hypertension screening." The Kaohsiung journal of medical sciences 2007; 23.1: 17-24. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004 ;25(6):484-91. Gaziano, Thomas A., et al. "Cost-Effectiveness analysis of hypertension guidelines in South Africa." Circulation. 2005; 112.23: 3569-3576. Gaziano, Thomas A., et al. "Hypertension education and adherence in South Africa: a cost-effectiveness analysis of community health workers." BMC public health. 2014; 14.1: 240. Guo, X., et al. "The prevalence and heterogeneity of prehypertension: a meta-analysis and meta-regression of published literature worldwide." Cardiovascular journal of Africa. 2012; 23.1: 44-50. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999;353:611– 616. Hasebe, Naoyuki, Kenjiro Kikuchi, and NICE Combi Study Group. "Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study." Journal of hypertension. 2005; 23.2: 445-453. Hsieh HM, Gu SM, Shin SJ, Kao HY, Lin YC, Chiu HC. Cost-effectiveness of a diabetes pay-for-performance program in diabetes patients with multiple chronic conditions. PloS one. 2015; 10.7: e0133163. Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, Chalmers TC. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med. 1994;121(5):355-62. JNC 7 Express. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. U. S. Department of health and human services. NIH publication, 2003. Kaambwa, Billingsley, et al. "Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis." European journal of preventive cardiology 2014; 21.12: 1517-1530. Kearney, Patricia M., et al. "Global burden of hypertension: analysis of worldwide data." The lancet 2005; 365.9455: 217-223. Lawes, Carlene MM, Stephen Vander Hoorn, and Anthony Rodgers. "Global burden of blood-pressure-related disease, 2001." The Lancet 2008; 371.9623: 1513-1518. Lüders, Stephan, et al. "The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure–a prospective, randomized, controlled prevention trial of the German Hypertension League." Journal of hypertension 2008; 26.7: 1487-1496. Moran AE, Odden MC, Thnataveerat A, et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015 23;372(17):1677. Naghavi, Morteza, et al. "The first SHAPE (screening for heart attack prevention and education) guideline." Critical pathways in cardiology 2006; 5.4: 187-190. Nelemans PJ, Kessels AG, De Leeuw P, De Haan M, van Engelshoven J. The cost-effectiveness of the diagnosis of renal artery stenosis. Eur J Radiol 1998;27:95–107. Ordunez, Pedro, and Norm RC Campbell. "Beyond the opportunities of SDG 3: the risk for the NCDs agenda." The Lancet Diabetes & Endocrinology 2016; 4.1: 15-17. Pan, W. H., et al. "Prevalence, awareness, treatment and control of hypertension in Taiwan: results of Nutrition and Health Survey in Taiwan (NAHSIT) 1993-1996." Journal of human hypertension 2001; 15.11: 793. Paul A. James, MD; Suzanne Oparil, MD; Barry L. Carter, PharmD, et al;. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2013; E1-E14 Pimenta, Eduardo, and Suzanne Oparil. "Prehypertension: epidemiology, consequences and treatment." Nature Reviews Nephrology 2010;6.1: 21-30. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13. Rose G. Sick individuals and sick populations. 1985. Bull World Health Organ 2001;79: 990-6. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10. Tseng, Chuen-Den, et al. "A predictive model for risk of prehypertension and hypertension and expected benefit after population-based life-style modification (KCIS No. 24)." American journal of hypertension. 2012; 25.2: 171-179. Vartiainen E , Jousilahti P, Alfthan G et al. Cardiovascular risk factor changes in Finland, 19721997. Int. J. Epidemiol. 2000;29:49-56. Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-47 Wright, E. Pamela, et al. "Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam." PloS one. 2016; 11.5: e0155699. Yen, Amy MF., and Tony HH. Chen. "Kinetic epidemiological model for elucidating sexual difference of hypertension (KCIS no. 20)." Journal of evaluation in clinical practice. 2011;17.1: 130-135.
|